SecBot SecBot
8-K ·Filed Jun 8, 2026

LAB

STANDARD BIOTOOLS INC.
BULLISH
Impact 7/10
Horizonmonths Processed5mo ago SEC0001104659-26-071195
Killer combo: Material agreement + unregistered equity (likely PIPE/convertible)
Actionable Insight ▲ Bullish

LAB shares may reprice on the transformative nature of the deal (public vehicle for Treeline's pipeline vs. legacy tools business). The narrow net cash band ($449M-$451M) limits downside for LAB holders but the 84%/16% split means most value comes from Treeline's clinical assets. Monitor the S-4 filing for pro forma financials and the timeline for HSR clearance and shareholder vote. CVR value is highly uncertain and speculative.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.8032
T+0 close · Jun 8, 2026 · via day close
Latest settled
−19.01%
T+60 · $0.6505
Vs SPY
−22.06%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 8 $0.8032entry
  2. T+1 · 5mo ago +10.33%α +10.63% · $0.8862
  3. T+5 · 5mo ago +5.63%α +3.52% · $0.8484
  4. T+20 · 4mo ago +10.47%α +8.84% · $0.8873
  5. T+60 · 3mo ago −19.01%α −22.06% · $0.6505
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Standard BioTools (LAB) announced a transformative merger with private biotech Treeline Biosciences in an all-stock reverse-merger transaction. Treeline is valued at $2.5 billion, while LAB is valued at ~$460M based on net cash at closing. Former Treeline stockholders will own ~84% of the combined company on a fully diluted basis, with LAB holders retaining ~16%. LAB also expects to issue contingent value rights (CVRs) to its stockholders tied to proceeds from Legacy Business monetization and other sources, capped at 76 million shares. The deal requires LAB shareholder approval and is expected to close in H2 2026.

Key Financial Metrics

Deal Type
merger

Key Facts

  • Reverse merger: Treeline valued at $2.5B; LAB valued at ~$460M (implied by net cash floor of $449M).
  • LAB shareholders will hold ~16% of the combined company; Treeline stockholders ~84%.
  • Exchange ratio based on relative equity values: $2.5B for Treeline, $460M for LAB with net cash adjustment bands ($449M floor, $451M ceiling).
  • Combined company to be named Treeline Biosciences Holdings, Inc.; LAB will effect a reverse stock split.
  • LAB will issue CVRs to its stockholders (one per share), paying 76M share-cap of common stock from net proceeds of Legacy Business sales, Illumina payments, and other sources over 5 years.
  • Executed voting agreements covering ~39% of LAB shares in favor of the deal.
  • Closing conditions include HSR clearance, Nasdaq listing approval, and LAB stockholder approval.

Financial Impact

All-stock merger; Treeline valued at $2.5B, LAB valued at ~$460M based on net cash at close ($449M floor). The exchange ratio implies significant value transfer to Treeline holders (~84% pro forma ownership).

equity valuedilutioncapital structure

Risk Factors

  • LAB shareholder vote required; potential opposition given low pro forma ownership (16%).
  • HSR review and other regulatory clearances may delay or block closing.
  • Execution risk on Legacy Business monetization and wind-down (affects CVR payouts).
  • Treeline's preclinical/clinical pipeline carries inherent drug development risk.
  • Dilutive to LAB holders from 100% to ~16% pro forma ownership.

Market Snapshot

Exchange
Nasdaq
Sector
Laboratory Analytical Instruments
Analyst Consensus
67% bullish (6 analysts)

Investment Themes

Industrials & Manufacturing

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-071195
Document: tm2617100d1_ex10-3.htm0001104659-26-071195
Document: tm2617100d1_ex10-1.htm0001104659-26-071195
Document: tm2617100d1_8k.htm0001104659-26-071195
Document: tm2617100d1_ex99-2.htm0001104659-26-071195

Track record

23 reports on LAB

Performance horizon

6 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +17.95% at T+20 after the Feb 24, 2026 report. 8 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today 425 Neutral 4/10 Entry price pending
  2. Nov 16, 2026today 8-K Neutral 3/10 Entry price pending
  3. Nov 3, 202613d ago 425 Neutral 3/10 Entry $0.6108 to $0.6160 Now $0.6200 +1.51% ▲ +0.85% −0.80% vs SPY
  4. Nov 3, 202613d ago 8-K Neutral 4/10 Entry $0.6108 to $0.6160 Now $0.6200 +1.51% ▲ +0.85% −0.80% vs SPY
  5. Nov 3, 202613d ago Press Release Neutral 3/10 Entry $0.6108 to $0.6160 Now $0.6200 +1.51% ▲ +0.85% −0.80% vs SPY
  6. Oct 22, 202626d ago EFFECT Neutral 4/10 Entry $0.6400 to $0.6056 Now $0.6200 −3.12% ▼ −5.38% −4.85% vs SPY
  7. Oct 21, 202626d ago S-4/A Bearish 7/10 Entry $0.6500 to $0.6400 Now $0.6200 +4.62% ▲ +1.54% +0.36% vs SPY
  8. Oct 9, 20265w ago S-4/A Neutral 6/10 Entry $0.6578 to $0.6589 Now $0.6200 −5.75% ▲ +0.17% +0.18% vs SPY
  9. Oct 5, 20266w ago 425 Neutral 5/10 Entry $0.7220 to $0.6787 Now $0.6200 −14.13% ▼ −6.00% −5.76% vs SPY
  10. Oct 5, 20266w ago 8-K Neutral 4/10 Entry $0.7220 to $0.6787 Now $0.6200 −14.13% ▼ −6.00% −5.76% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens Wed (9h 49m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 8, 2026